Genitourinary Cancers | Specialty

Dr. Robert Alter on ASCO GU-Kidney Cancer Findings

March 14th 2011

Dr. Alter Discusses Research at JTCC

March 14th 2011

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Dr. Alter on Kidney Cancer Drugs From 2005-2010

March 14th 2011

Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.

Advances in Kidney Cancer Over the Past Several Years

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Explains Advancements in Kidney Cancer Over the Past Several Years

Advice for Newly Diagnosed Kidney Cancer Patients

March 14th 2011

Ana M. Molina, MD, Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Gives Advice for Newly Diagnosed Kidney Cancer Patients

Pazopanib, Sunitinib and Other Recent Clinical Trials

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Talks About Pazopanib, Sunitinib and Other Recent Clinical Trials

Clinical and Economic Considerations for the Use of Erythropoiesis-Stimulating Agents

March 4th 2011

Erythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase

A Review of Data on Optimal Sequencing and Combinations of Current Therapies in Renal Cell

March 4th 2011

The past 2 to 3 decades saw a palpable therapeutic nihilism associated with the management of patients with advanced renal cell carcinoma (RCC), interrupted briefly by the initial excitement regarding high-dose interleukin-2.

Flash Findings

August 17th 2010

Fast biotech facts and figures. In this issue: 1) Cancer Risk Factors and Mortality 2) Bladder Cancer 3) Testicular Cancer 4) Breast Cancer

NCCN Updates Guidelines for Kidney and Cervical Cancer

July 8th 2010

The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 21 leading cancer centers worldwide, develops and publishes clinical practice guidelines to promote the importance of continuous quality improvement. The primary goal of all its initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

Updated Guidelines on Non-Muscle Invasive Bladder Cancer

June 24th 2010

Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.

Staying Focused in Turbulent Times

May 24th 2010

When the market is volatile, people think about their financial future. With current market events as turbulent as they are, you may be concerned about their potential impact on your 401(k) account. During times like this, it is more important than ever to follow certain basic, time-tested principles of investing.

Can New Technologies Be Used to Predict Treatment Response in Cancer Patients?

March 20th 2009

The next leap forward in cancer treatment will see physicians tailoring treatments based on patients' individualized tumor profiles.